Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong

Related Videos

Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS -- such as that provided by FoundationOne Medicine -- as opposed to targeted, hotspot panels? Video

Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS -- such as that provided by FoundationOne Medicine -- as opposed to targeted, hotspot panels?

Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS — such as that provided by FoundationOne Medicine — as opposed to targeted, hotspot panels? What critical information does the report provide?

What is the role of NGS in triple-negative breast cancer? Are there actionable insights than emerge from full exome sequencing in patients with TNBC who have progressed on standard therapies? Video

What is the role of NGS in triple-negative breast cancer? Are there actionable insights than emerge from full exome sequencing in patients with TNBC who have progressed on standard therapies?

What is the role of NGS in patients with triple-negative breast cancer? Is it controversial? Are there actionable insights than emerge from full exome sequencing in patients with TNBC who have progressed on standard therapies?

What is the role of hybrid capture-based NGS for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Where can NGS offer actionable insights and specific treatment roadmaps? Video

What is the role of hybrid capture-based NGS for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Where can NGS offer actionable insights and specific treatment roadmaps?

What is the role of hybrid capture-based NGS — full exome sequencing — for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Can you cite some specific patient examples where NGS can offer actionable insights ...

How will hybrid capture-based NGS improve identification of patients with breast cancer who will benefit from trastuzumab therapy? Video

How will hybrid capture-based NGS improve identification of patients with breast cancer who will benefit from trastuzumab therapy?

How will hybrid capture-based NGS improve identification of patients with breast cancer who will benefit from trastuzumab therapy?

Can you provide an example of a luminal A patient with metastatic breast cancer in whom treatment was optimized by NGS-based, comprehensive genomic assessment? Video

Can you provide an example of a luminal A patient with metastatic breast cancer in whom treatment was optimized by NGS-based, comprehensive genomic assessment?

Can you provide an example of a luminal A patient with metastatic breast cancer in whom treatment was optimized by NGS-based, comprehensive genomic assessment?

What is the role of NGS for identifying “HER-2 enrichment” therapy? What is the situation in Asia as far deploying NGS in patients with breast cancer? Video

What is the role of NGS for identifying “HER-2 enrichment” therapy? What is the situation in Asia as far deploying NGS in patients with breast cancer?

What is the role of NGS for identifying “HER-2 enrichment” therapy? What is the situation in Asia as far deploying NGS in patients with breast cancer?

How is hybrid-based NGS leading to improved stratification of patients with breast cancer? Video

How is hybrid-based NGS leading to improved stratification of patients with breast cancer?

How is hybrid-based NGS leading to improved stratification of patients with breast cancer?

Does FoundationOne's comprehensive genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Video

Does FoundationOne's comprehensive genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal?

Does FoundationOne’s comprehensive genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically ...

What is the rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations? Video

What is the rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations?

What is the clinical rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations over time?